VRNA
Income statement / Annual
Last year (2024), Verona Pharma plc's total revenue was $42.28 M,
and the percentage change from the previous year is not available.
In 2024, Verona Pharma plc's net income was -$173.42 M.
See Verona Pharma plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$42.28 M |
$0.00 |
$458,000.00 |
$40.00 M |
$0.00 |
$2,351.00 |
$2,783.00 |
$1.84 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$2.58 M
|
$679,624.00
|
$346,000.00
|
$0.00
|
$627,846.00
|
$512,111.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$39.70 M
|
-$679,624.00
|
$112,000.00
|
$40.00 M
|
-$627,846.00
|
-$509,760.00
|
$2,783.00
|
$1.84 M
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.94
|
0
|
0.24
|
1
|
0
|
-216.83
|
1
|
1
|
0
|
0
|
| Research and Development Expenses |
$44.57 M
|
$17.28 M
|
$49.28 M
|
$79.41 M
|
$44.51 M
|
$43.89 M
|
$24.48 M
|
$32.05 M
|
$5.58 M
|
$10.76 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$7.20 M
|
$11.66 M
|
$29.77 M
|
$8.99 M
|
$7.99 M
|
$8.10 M
|
$2.89 M
|
$2.51 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$19.38 M
|
$22.24 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$149.75 M
|
$49.87 M
|
$26.58 M
|
$33.91 M
|
$29.77 M
|
$8.99 M
|
$7.99 M
|
$8.10 M
|
$2.89 M
|
$2.51 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$9.63 M
|
-$15.63 M
|
-$8.27 M
|
$527,088.00
|
$16,495.00
|
$23,000.00
|
$1.07 M
|
$1.17 M
|
| Operating Expenses |
$194.32 M
|
$67.15 M
|
$66.23 M
|
$97.68 M
|
$66.01 M
|
$53.41 M
|
$32.48 M
|
$40.16 M
|
$8.49 M
|
$13.29 M
|
| Cost And Expenses |
$196.91 M
|
$67.83 M
|
$66.57 M
|
$97.68 M
|
$66.01 M
|
$53.41 M
|
$32.48 M
|
$40.16 M
|
$8.49 M
|
$13.29 M
|
| Interest Income |
$15.26 M
|
$12.81 M
|
$2.82 M
|
$14,000.00
|
$121,000.00
|
$988,619.00
|
$1.09 M
|
$466,235.00
|
$106,776.00
|
$66,358.00
|
| Interest Expense |
$23.54 M
|
$2.06 M
|
$521,000.00
|
$340,000.00
|
$35,000.00
|
$221,587.00
|
$0.00
|
$98,652.00
|
$104,516.00
|
$0.00
|
| Depreciation & Amortization |
$1.06 M
|
$679,624.00
|
$636,000.00
|
$629,000.00
|
$627,846.00
|
$512,111.00
|
$124,352.00
|
$166,222.00
|
$76,029.00
|
$78,691.00
|
| EBITDA |
-$138.53 M |
-$52.47 M |
-$67.29 M |
-$42.19 M |
-$47.81 M |
-$32.17 M |
-$25.50 M |
-$29.64 M |
-$6.96 M |
-$8.92 M |
| EBITDA Ratio |
-3.28
|
0
|
-136.81
|
-1.43
|
0
|
-22018.22
|
-11235.05
|
-21.46
|
0
|
0
|
| Operating Income Ratio |
-3.66
|
0
|
-144.36
|
-1.83
|
0
|
-22912.22
|
-11668.2
|
-21.84
|
0
|
0
|
| Total Other Income/Expenses Net |
-$8.50 M
|
$12.62 M
|
$7.30 M
|
-$1.37 M
|
$6.78 M
|
$8.99 M
|
$1.46 M
|
$4.55 M
|
$1.05 M
|
-$28,000.00
|
| Income Before Tax |
-$163.13 M
|
-$55.21 M
|
-$68.45 M
|
-$55.59 M
|
-$65.00 M
|
-$51.41 M
|
-$30.62 M
|
-$34.06 M
|
-$7.37 M
|
-$13.22 M
|
| Income Before Tax Ratio |
-3.86
|
0
|
-149.45
|
-1.39
|
0
|
-21865.41
|
-11003.42
|
-18.5
|
0
|
0
|
| Income Tax Expense |
$10.29 M
|
-$632,441.00
|
$253,000.00
|
-$18,000.00
|
$146,000.00
|
-$9.53 M
|
-$5.37 M
|
-$6.36 M
|
-$1.18 M
|
-$2.24 M
|
| Net Income |
-$173.42 M
|
-$54.37 M
|
-$68.70 M
|
-$55.57 M
|
-$65.15 M
|
-$41.88 M
|
-$25.25 M
|
-$27.70 M
|
-$6.19 M
|
-$10.99 M
|
| Net Income Ratio |
-4.1
|
0
|
-150
|
-1.39
|
0
|
-17813.67
|
-9073.85
|
-15.05
|
0
|
0
|
| EPS |
-0.27 |
-0.09 |
-0.13 |
-0.12 |
-0.25 |
-0.4 |
-0.24 |
-0.32 |
-0.18 |
-0.54 |
| EPS Diluted |
-0.27 |
-0.0857 |
-0.13 |
-0.12 |
-0.25 |
-0.4 |
-0.24 |
-0.32 |
-0.18 |
-0.54 |
| Weighted Average Shares Out |
$652.31 M
|
$604.10 M
|
$528.46 M
|
$473.18 M
|
$262.93 M
|
$105.32 M
|
$105.10 M
|
$87.74 M
|
$33.50 M
|
$20.19 M
|
| Weighted Average Shares Out Diluted |
$652.31 M
|
$634.14 M
|
$529.07 M
|
$473.19 M
|
$262.93 M
|
$105.33 M
|
$105.11 M
|
$87.75 M
|
$33.50 M
|
$20.20 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
